Introduction
Prostate cancer is the most common solid tumor and one of the leading causes of cancer-related death among American men. [ 1 ] Radiotherapy and/or surgery with or without androgen deprivation are used for management of early stage, organconfi ned prostate cancer. A subset of early stage cancer may progress to an aggressive metastatic disease, which does not respond to androgen deprivation. Chemotherapeutic approaches are used for treating metastatic prostate cancer. The development of androgen resistance and systemic off-target toxicities of conventional chemotherapeutic drugs such as docetaxel and mitoxantrone are major clinical challenges. [ 2 , 3 ] There is a need for safe and effective therapies that are based on specifi c targeting of immunotoxins to tumors. Tumor cells often express high levels of surface receptors or other molecules that distinguish them from other cells. Ligands designed to bind to tumorspecifi c receptors can be conjugated to cytotoxic drugs or toxins and the resulting conjugates provide a tumor targeted drug delivery system for safe and effective therapy. [ 4 ] Further research along these lines may lead to molecularly targeted individualized therapy.
Prostate-specifi c membrane antigen (PSMA) is over-expressed on the surface of certain prostate cancer cells. It is noteworthy that PSMA expression is particularly pronounced when prostate cancer progresses to late stage and becomes androgen-independent and metastatic. [ 5 ] PSMA expression in certain prostate cancer cells is 1000-fold higher than in normal prostate tissue. [ 6 ] PSMA is also expressed on the neovascular endothelium of a wide variety of human solid tumors, but is not expressed in the blood vessels of normal tissue. [ 7 ] These fi ndings have prompted the use of monoclonal antibody (mAb) of PSMA for sensitive and specifi c tumor imaging [ 8 ] as well as targeted drug delivery for treating prostate cancer and other solid tumors. [ 9 ] PSMA antibody or its fragments, such as single-chain antibody fragments (scFv), can deliver cytotoxic agents into PSMAexpressing cells. [ 10 ] scFv consists of the variable heavy chain (V H ) and the variable light chain (V L ) of an antibody connected by a fl exible peptide linker and, due to its small size, exhibits better tumor penetration, improved tumor distribution, and faster blood clearance than a full antibody when it is used as a ligand for targeted drug delivery. [ 11 ] The truncated form of diphtheria toxin (DT390) constructs incorporated in the immunotoxin exhibits targeted cytotoxicity [ 12 , 13 ] and bioactivity in vivo . [ 14 , 15 ] The DT-based anti-CD3 bivalent immunotoxin, A-dmDT390-bisFv (UCHT1), has been shown to bind to its target and depletes T cells effectively. [ 16 ] This immunotoxin has undergone preclinical studies [ 17 , 18 ] and is currently in clinical trials for treating cutaneous T-cell lymphoma (clinical trial identifi er NCT00611208). In general, bivalent immunotoxins containing two scFv units have higher affi nity and effi cacy towards the targeted cells than those containing one scFv. [ 13 , 19 ] It has also been shown that the format of scFv bivalency strongly affects binding affi nity and immunotoxin cytotoxicity, depending on the antibody Fv sequences. The anti-monkey CD3 bivalent immunotoxin with a fold-back singlechain diabody, A-dmDT390-scfbDb(207), showed a 5-to 7-fold enhanced bioactivity over that containing two tandem unites of scFv (biscFv). [ 19 ] To effectively deliver DT390 and enhance the specifi city of its targeting to PSMA-expressing cells, we constructed an anti-PSMA fold-back single-chain diabody (scfbDb, Figure 1 A) based on the Fv sequences of the murine anti-PSMA antibody J591 and fused it to the C-terminus of DT390 using the approach similar to that for constructing anti-CD3 immunotoxin A-dmDT390-scfbDb(207). [ 19 ] As shown in Figure 1 B and C, the bivalent anti-PMSA immunotoxin, A-dmDT390-scfbDb(PSMA), has a sequence of DT390-L1-V L -L1-V H -L2-V L -L1-V H where L1 is a fi ve-residue linker and L2 is the longer (G 4 S) 3 linker, permitting interactions between the distal and proximal V L /V H domains. Preliminary studies showed that the scfbDb bound to the extracellular domain of PSMA with a higher affi nity than biscFv and single scFv formats at a ratio of 7:2.5:1 (scfbDb:biscFv:scFv). This fi nding indicates that the scfbDb (PSMA) may be more sensitive and specifi c for targeted imaging and therapy. Previous in vitro studies have further demonstrated that the anti-PSMA fold-back diabody effi ciently mediates the entry of the truncated toxin across the cell membrane into the cytosol and the foldback format immunotoxin is 18-to 30-fold more potent than the biscFv format against monolayer LNCaP cancer cells. [ 20 ] For targeted immunotoxin therapy, it is important to determine the response of tumor cells to therapy. It would be useful if the target molecules expressed on the tumor cells could be identifi ed before treatment, and the therapeutic dynamics and mechanisms could be imaged noninvasively during the targeted immunotoxin therapy. In this report, we laid the groundwork for evaluating the targeting specifi city and therapeutic potential of the immunotoxin construct A-dmDT390-scfbDb(PSMA) with noninvasive optical imaging.
In this study, A-dmDT390-scfbDb(PSMA) was conjugated to Alexa Fluor 680 dye and used to investigate its utility for tumorspecifi c imaging and treatment. For this purpose, prostate cancer cells were grown in vitro as monolayer cultures and in vivo as solid tumor xenografts in athymic nude mice. The results confi rmed that A-dmDT390-scfbDb(PSMA) immunotoxin had specifi c tumor targeting property in addition to a distinct and potent anticancer activity against PSMA-positive prostate cancer but not against PSMA-negative prostate cancer.
Results and Discussion
PSMA is known to be highly expressed and rapidly internalized in malignant prostate cancer cells. However, it is minimally expressed in benign tumors and normal tissues. The PSMA antibody fragment scFv has been used to bind specifi cally to prostate cancer cells for prostate cancer therapy [ 21 , 22 ] and some PSMA-targeted therapeutics have been investigated in clinical trials. [ 23 , 24 ] In this study, we demonstrated that the conjugate of a fold-back single-chain diabody of anti-PSMA monoclonal antibody fused to the translocation domains of diphtheria toxin (A-dmDT390-scfbDb(PSMA)) inhibited the growth of PSMApositive LNCaP cancer cells both in vitro and in vivo but not the growth of PSMA-negative PC-3 cells. The specifi c toxicity towards LNCaP cells indicated that scfbDb(PSMA) bound specifi cally to the PSMA antigen on the cell membrane and effectively delivered DT390 into the PSMA-expressing cells to induce cytotoxicity.
PSMA is Overexpressed in LNCaP but not in PC-3 Cells
The expression of PSMA in LNCaP and PC-3 cells was determined with immunofl uorescence staining and Western blotting. The results showed high levels of PSMA expression in LNCaP cells, but not in PC-3 cells ( Figure 2 ).
A-dmDT390-scfbDb(PSMA) Inhibits Proliferation of LNCaP Cells
The inhibitory effects of A-dmDT390-scfbDb(PSMA) on the proliferation and viability of LNCaP cells and PC-3 cells were 
Cellular Uptake and Accumulation are High in LNCaP Cells but not in PC3 Cells
A-dmDT390-scfbDb(PSMA) was labeled with Alexa Fluor 680. The cellular uptakes and accumulations of the Alexa Fluor 680-labeled immunotoxin were detected with fl uorescence microscopy and fl ow cytometry. As shown in Figure 4 Figure S2 ). The heterogeneous distribution of the signal observed under microscopy is largely due to the different stages of cell proliferation and various expression levels of PSMA of the cells.
A-dmDT390-scfbDb(PSMA) Induces Cell Arrest and Apoptosis of LNCaP Prostate Cancer Cells
LNCaP cells were incubated with graded concentrations (0 to 5 n M ) of A-dmDT390-scfbDb(PSMA) for 24 hours and stained with propidium iodide (PI), which binds with DNA. The fraction of cells with sub-diploid DNA content was measured with fl ow cytometry. As shown in Figure 7 A, treatment with increasing doses of unlabeled immunotoxin resulted in dose-dependent increases in the S phase population with concomitant decreases in the G2 phase population of LNCaP cells. However, this effect of the immunotoxin was not evident in PC-3 cells. Similarly, trypan blue dye staining showed signifi cantly increased staining of nonviable cells in LNCaP cultures, but not in PC-3 cell cultures treated with the immunotoxin. The 48 hours DNA content frequency histogram was similar to 24 hour histogram and shown in Figure S3 . Light microscopy also showed higher rates of apoptosis in LNCaP cells after incubation with increasing amounts of A-dmDT390-scfbDb(PSMA) (Figure 7 B) . Fluorescence microscopy showed an increase of green fl uorescence signal on the cell membrane due to apoptosis (FITC-labeled annexin V antibody bound with apoptotic cells) when the concentration of the immunotoxin was increased from 0.1 n M to 1 n M . The red fl uorescence signal increased (due to DNA binding to PI in necrotic cells) when cells were treated with increased dose of immunotoxin, i.e., from 5 n M and 10 n M immunotoxin (Figure 7 B) .
Diphtheria toxin exerts its toxicity towards eukaryotic organisms through inactivation of the polypeptide chain EF-2 (Elongation Factor 2). The inactivation results in inhibition of protein synthesis and induction of apoptosis. [ 25 ] As a truncated form of diphtheria toxin, DT390, is widely known for inducing cellular toxicity through targeted delivery via a ligand component. The immunotoxins constructed with DT390 are reported to have high toxicity to activated T cells. [ 14 , 26 ] However, little is known about the process of targeted cell apoptosis induced by DT390 in tumor cells. In this study, the immunotoxin of A-dmDT390-scfbDb(PSMA) effi ciently induced apoptosis in population in LNCaP cell cultures. These may have some implications for the cytotoxicity of the immunotoxin in vitro .
A-dmDT390-scfbDb(PSMA) Targets LNCaP but not PC-3 Solid Tumor Xenografts in Live Mice
LNCaP cells and PC-3 cells were implanted on the lower left fl ank of athymic nude mice to test the targeting effi ciency of A-dmDT390-scfbDb(PSMA) in prostate tumors. The tumor was allowed to grow to about 5 mm in diameter. Alexa Fluor 680 dye labeled A-dmDT390-scfbDb(PSMA) (100 μ L, 200 μ g/mL) or Alexa Fluor 680 dye alone was administered as a single bolus via tail vein injection. The whole animal was then imaged at different time points after injection. In this study, near infrared fl uorescent imaging was used to confi rm the tumor targeting effectiveness of the immunotoxin in LNCaP tumors. Optical imaging provides a dynamic, noninvasive real-time in vivo imaging technique for monitoring the uptake of fl uorescent probes in tumor-bearing animals. This optical approach can be used to monitor gene delivery and drug accumulation in tumors. [27] [28] [29] As shown in Figure 8 , accumulation of the fl uorescence signal from the labeled immunotoxin was detectable in LNCaP tumors as early as 30 minutes after injection. The fl uorescent signal in LNCaP tumors showed an increase during the fi rst 6 hours after injection, followed by a gradual decrease (Figure 8 A) . The signal from the free Alexa Fluor 680 dye was rapidly detectable throughout the whole body. However, no obvious accumulation of the Alexa Fluor 680 dye was observed in the tumors (Figure  8 B) . In PC-3 tumor models, both Alexa Fluor 680 labeled A-dmDT390-scfbDb(PSMA) and Alexa Fluor 680 dye showed increased fl uorescent signals throughout the whole body during the fi rst 8 hours after injection. However the fl uorescent signal showed no obvious targeting to and accumulation in the tumors ( Figure S4 ).
A-dmDT390-scfbDb(PSMA) Inhibits LNCaP Tumor Growth
The tumor-specifi c inhibitory effect of A-dmDT390-scfbDb(PSMA) was studied on the PSMA-positive LNCaP tumors and the PSMA-negative PC-3 tumors grown as solid tumor xenografts in athymic nude mice. 
PSMA-positive LNCaP cells. Flow cytometry analysis of the cell cycle parameters showed that the immunotoxin caused an increase in S phase population and a decrease in G2 phase
in vitro ( Figure 3 ) and in vivo ( Figure 9 ) suggests that the immunotoxin can selectively bind to, and be internalized into, PSMAexpressing cells. This specifi c targeting in vivo may be responsible for the inhibitory effect of A-dmDT390-scfbDb(PSMA) on the PSMA-positive LNCaP tumor growth, but not on the PSMA-negative PC-3 tumor growth. The fi ndings suggest that this immunotoxin construct has considerable promise and potential for prostate cancer treatment.
Immunotoxins generated by full length anti-PSMA monoclonal antibody [ 30 , 31 ] or its scFv [ 32 ] exhibit specifi c cytotoxicity and capability to inhibit PSMA-positive prostate tumor growth. However, there are few clinical trials evaluating the clinical potential of immunotoxins linked to PSMA antibody. An important fi nding of this study was the effi cacy of the A-dmDT390-scfbDb(PSMA) immunotoxin against PSMA-positive prostate cancer cells and the lack of binding and cytotoxic effect against PSMA-negative prostate cancer cells. This suggests that inappropriate use of this immunotoxin for treating PSMA-negative tumors may run the risk of unintended systemic toxicity. It is imperative to confi rm the presence of PSMA on the tumor cells before initiating therapy with the immunotoxin used in our studies because some prostate cancers do not express PSMA.
Conclusion
The A-dmDT90(390)-scfbDb(PSMA) immunotoxin used in this study selectively accumulates in LNCaP cells and tumors that overexpress PSMA. As a consequence of this uptake, LNCaP cells underwent S phase arrest and apoptosis. Intraperitoneal injection of the immunotoxin caused regression of LNCaP solid tumor xenografts in nude mice. Such accumulation and therapeutic response was not seen in PC3 cells and xenografts. This is due to the fact that PC3 cells and tumors are defi cient in PSMA expression. Optical imaging experiments confi rmed effi cient targeted uptake of NIR labeled immunotoxin by PSMA expressing LNCaP cells and solid tumor xenografts in nude mice.
Our study showed that the use of this immunotoxin might be benefi cial to individuals with a PSMA-positive prostate tumor. Optical imaging on the individual patient may be processed to determine the expression of PSMA and monitor the effi cacy of immunotoxin therapy using the methods described in this paper. This approach will enable us to identify patients who are likely to benefi t from treatment with A-dmDT390-scfbDb(PSMA). The fl uorescently-labeled immunotoxin is potentially useful for targeted theranostics and personalized medicine. Each mouse was given A-dmDT390-scfbDb(PSMA) (10 μ g) via intraperitoneal injection for six consecutive days. A-dmDT390-scfbDb(PSMA) signifi cantly inhibited LNCaP tumor growth while not affecting PC-3 tumor growth ( Figure 9 A and B,  Figure 10 ). At the end of treatment, the tumors were surgically removed and weighed. The average LNCaP tumor weight in the treatment group was 0.27 ± 0.09 g, which was significantly lower than the tumor weight in the untreated control group (0.67 ± 0.11 g) ( P < 0.05, Figure 9 C). The average weight of the treated PC-3 tumors was not signifi cantly different from the average weight of untreated PC-3 tumors in the control group ( P > 0.05, Figure 9 C ). There was no difference for the body weights between the LNCaP tumor-bearing mice and PC-3 tumor-bearing mice, whether or not the animals were treated with the immunotoxin ( P > 0.05). Figure 8 shows rapid accumulation of A-dmDT390-scfbDb(PSMA) immunotoxin in LNCaP tumors, whereas no fl uorescent signal was detected in PC-3 tumors. High intensity of fl uorescent signals from Alexa Fluor 680 labeled A-dmDT390-scfbDb(PSMA) immunotoxin was also observed in the kidneys, suggesting that the immunotoxin or degraded fragments might be excreted through the kidneys. The selective cytotoxicity of A-dmDT390-scfbDb(PSMA) immunotoxin both
Experimental Section
Cell Lines : Human prostate cancer cell lines LNCaP and PC-3 were purchased from ATCC (American Type Culture Collection, Manassas, VA). LNCaP and PC-3 cells were maintained as exponentially growing monolayer cultures in RPMI 1640 medium and DMEM, respectively. Both media were supplemented with L-glutamine (2 m M ), penicillin and streptomycin (50 μ g/mL each), and 10% heat-inactivated fetal bovine serum. The cells were maintained in culture at 37 ° C with 5% CO 2 in air and 95% humidity.
Expression and Purifi cation of A-dmDT390-scfbDb(PSMA) Protein : A-dmDT390-scfbDb(PSMA) was expressed in a DT-resistant Pichia pastoris strain. The immunotoxin was produced in shake fl ask culture and purifi ed by three purifi cation steps, Phenyl Sepharose hydrophobic interaction chromatography, Q Sepharose anion exchange chromatography and Superdex 200 gel fi ltration chromatography. [ 20 ] Cellular PSMA Staining: LNCaP and PC-3 cells were plated in 8-well chamber slides with 1 × 10 4 cells in medium (0.5 mL) in each well. After 24 hours, cells were washed with Dulbecco's phosphate-buffered saline (DPBS) and fi xed in 3.7% paraformaldehyde. The cells were permeabilized with 0.2% Triton-X 100 and blocked with 1% bovine serum albumin (BSA) in Hank's buffered salt solution (HBSS) for 1 hour. The cells were then incubated with a rabbit monoclonal anti-PSMA antibody (Abcam, Cambridge, MA) at a dilution of 1:200 to a fi nal concentration of 1 μ g/mL. After washing the cells with HBSS, goat antirabbit immunoglobulin G conjugated with Alexa Fluor 680 (Invitrogen, Carlsbad, CA) was added to the blocking solution at a fi nal concentration of 2 μ g/mL and incubated at room temperature for 1 hour in the dark. The slides were washed three times with DPBS, and examined with a fl uorescence microscope.
Western Blot Analysis : LNCaP and PC3 cells were washed with DPBS and lysed with RIPA lysis and extraction buffer (Pierce Biotech, Rockford, IL). Protein concentrations were determined with the Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA). Fifty micrograms of proteins were separated by 8% SDS-PAGE electrophoresis and transferred to PVDF membranes. The membranes were blocked using 5% nonfat milk and probed separately for 2 hours at room temperature with primary antibodies for PSMA (Abcam) and β -Actin (Santa Cruz Biotechnology, Santa Cruz, CA). The membranes were then washed and probed with a 1:2000 dilution of peroxidaseconjugated secondary antibody, and detected with enhanced chemiluminescence (Amersham Life Sciences, Amersham, UK).
Cell Viability Assays : Cells were seeded in 96-well plates and cultured for 24 hours. The cells were then exposed to a graded range of concentrations of A-dmDT390-scfbDb(PSMA) (from 0 nM to 5 nM) for 48 hours. The viability of cells was measured with a MTT assay. MTT solution (100 μ L, 0.5 mg/mL in PBS) was added to each well. The plates were incubated for 4 hours at 37 ° C, and then dimethyl sulfoxide (100 μ L) was added to each well and incubated for 10 minutes at room temperature. The absorbance was measured at 570 nm using a plate reader. The half maximal inhibitory concentration (IC 50 ) of the immunotoxin was calculated using the SPSS software for performing statistical analysis. Assessment of Apoptosis : Annexin V binding was used to estimate apoptosis. Cells were fi rst exposed to a DNA-binding dye (PI) to detect sub-diploid population. The two prostate cancer cell lines (LNCaP and PC-3) were treated with 0.1, 0.5, and 1.0 μ M of A-dmDT390-scfbDb(PSMA) immunotoxin for 24 hours. Then, the cells were harvested with trypsinization, collected by centrifugation, and washed with DPBS. The collected cells were fi xed with 70% ethanol for 1 hour at 4 ° C. The fi xed cells were washed twice in DPBS, incubated with a solution containing RNase (100 μ g/mL) at 37 ° C in a water bath for 30 minutes, and then gently re-suspended in PI solution (1 mL, 50 μ g/mL with 3.8 μ M sodium citrate in DPBS). Lastly, the cells were incubated for 15 minutes in the dark at room temperature and analyzed using fl ow cytometry. The red fl uorescence signal from PI staining of individual cells was collected. Ten thousand cells of each sample were counted. For fl uorescence microscopy detection, 10,000 LNCaP cells were plated onto an 8-well chamber slide for 24 hours. After incubation with different concentrations of A-dmDT390-scfbDb(PSMA) for 48 hours, the cells were incubated with Annexin binding buffer (500 μ L). Annexin V-FITC (5 μ L) and PI (Abcam) (5 μ L) were added onto the cells, and cells were fi xed in 2% formaldehyde before visualization. The fi xed cells were examined under a fl uorescence microscope using separate fi lters for FITC and PI. The cells that bound Annexin V-FITC, which had undergone apoptosis, showed green staining on the plasma membrane, whereas for each image was 2 seconds. Regions of interest around tumor sites from the displayed images were identifi ed and emitted light was measured. The signal intensity was expressed as radiant effi ciancy in photons/second/cm 2 /steradian/( μ Watt/cm 2 ) (p/s/ cm 2 /sr/( μ W/cm 2 )). The contralateral non-tumorbearing leg muscle was selected as the background.
Endocytosis and Quantifi cation of A-dmDT390-scfbDb(PSMA) in Cells
Evaluation of Therapeutic Effi cacy: Tumor xenograft models were developed by subcutaneous inoculation of 5 × 10 6 LNCaP cells or 2 × 10 6 PC-3 cells mixed with matrigel (0.2 mL) into the lower left fl ank of fi ve-week-old male athymic nude mice. LNCaP tumors were allowed to develop for six weeks and PC-3 tumors for three weeks to reach the diameter of about 5 mm. The mice with LNCaP tumors or PC-3 tumors were divided randomly into two groups ( n = 10). A-dmDT390-scfbDb(PSMA) immunotoxin (200 μ g/kg) or BSA diluted in DPBS was administered via intraperitoneal injection to twice a day at 6 hour intervals (10 am and 4 pm) for 6 days. Tumor growth was monitored twice a week with MRI. The mice were anesthetized with 2% isofl urane in oxygen, positioned in the MRI probe, and taped with polyurethane foam to avoid involuntary motion. A Bruker 400MHz NMR machine (Bruker-Biospin, Billerica, MA) was used for MRI. A rapid acquisition with refocused echoes (RARE) sequence was used to acquire T2-weighted coronal images. The imaging parameters were: echo time 7.8 ms, RARE factor 16, effective echo time 39 ms, repetition time 3600 ms, number of averages 12, fi eld-of-view 27.0 mm × 25.6 mm, matrix size 192 × 256, and slice thickness 0.5 mm. The Medical Image Processing, Analysis, and Visualization application (CIT/NIH, Bethesda, MD) was used for image analysis. The tumor was manually segmented in each MRI image, the number of voxels within the boundary of tumor was counted and the total tumor volume was calculated.
Statistical Analysis : Statistical analysis was performed with the Student's t-test. Survival was assessed with the Kaplan-Meier method. A signifi cant correlation was inferred if a P value was < 0.05 by correlation analysis. All statistical tests were two-sided.
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Supporting Information is available from the Wiley Online Library or from the author. the cells that had lost membrane integrity due to necrosis showed red PI staining throughout the nuclei. To further determine the cytotoxicity of A-dmDT390-scfbDb(PSMA), the cells were routinely examined using trypan blue staining and under light microscopy. The cells permeable to trypan blue were considered nonviable.
Animal Tumor Model and Optical Imaging : All animal studies were carried out in accordance with the guidelines of the Howard University Institutional Animal Care and Use Committee. Five-week-old athymic male nude mice were inoculated subcutaneously with 5 × 10 6 LNCaP cells or 2 × 10 6 PC-3 cells mixed with matrigel (BD Biosciences, Bedford, MA) (0.2 mL) into the lower left fl ank. The tumors were allowed to reach 5-7 mm in diameter for imaging study. Six mice with LNCaP tumors and fi ve mice with PC-3 tumors were used to test the detection sensitivity and specifi city of imaging and the dynamic uptake of Alexa Fluor 680-labeled A-dmDT390-scfbDb(PSMA) in vivo . Three mice with LNCaP tumors and three mice with PC-3 tumors were used to test specifi c targeting of tumor by Alexa Fluor 680 labeled A-dmDT390-scfbDb(PSMA). Three mice with LNCaP tumors and two mice with PC-3 tumors were given an identical volume of DPBS and served as controls.
In vivo fl uorescence imaging of tumor-bearing mice was performed using the IVIS 200 Imaging System and Living Image software (Caliper Life Sciences, Hopkinton, MA). The mice were placed on a warmed (25 ° C) stage inside a light-tight camera box with continuous exposure to 2% isofl urane. The mice were given the Alexa Fluor 680 labeled A-dmDT390-scfbDb(PSMA) (100 μ L 2.06 μ M or 100 μ L 4.12 μ M ) or Alexa Fluor 680 dye via tail vein injection. The mouse was imaged every 10 minutes for the fi rst hour and then imaged every hour for 24 hours. The acquisition time 
